Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Nicole Goh

A/Prof Nicole Goh

Detection, Assessment and Management of Pulmonary Fibrosis

A/Prof Robyn Saw

A/Prof Robyn Saw

Practical Melanoma Management for GPs

Dr Bobby Chan

Dr Bobby Chan

Preventing Renal Failure in Type 2 Diabetes – New Options

Dr Victoria Hayes

Dr Victoria Hayes

Management of Post-Vaccination Reactions

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023